177
Views
3
CrossRef citations to date
0
Altmetric
Research Article

The effects of atorvastatin on oxidative stress in L-NAME-treated rats

, , , , , , & show all
Pages 591-597 | Received 06 Dec 2012, Accepted 25 Apr 2013, Published online: 12 Sep 2013

References

  • Gresser U, Gathof BS. Atorvastatin: gold standard for prophylaxis of myocardial ischemia and stroke – comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies. Eur J Med Res 2004;9:1–17.
  • Alvarez De Sotomayor M, Herrera MD, Marhuenda E, Andriantsitohaina R. Characterization of endothelial factors involved in the vasodilatory effect of simvastatin in aorta and small mesenteric artery of the rat. Br J Pharmacol 2000; 131:1179–87.
  • Ni W, Egashira K, Kataoka C, Kitamoto S, Koyanagi M, Inoue S, Takeshita A. Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase Inhibitors in a rat model of chronic Inhibition of nitric oxide synthesis. Cir Res 2001;89:415–21.
  • Halliwell B, Gutteridge J. Free radicals in biology and medicine. NY: Oxford University Press, 1999.
  • Chisolm GM, Steinberg D. The oxidative modification hypothesis of atherogenesis: an overview. Free Radic Biol Med 2000;28:1815–26.
  • Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 1996;7:69–76.
  • Rozenberg O, Rosenblat M, Coleman R, Shih DM, Aviram M. Paraoxonase1 (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. Free Radic Biol Med 2003;34:774–84.
  • Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998;101:1581–90.
  • Berlett BS, Stadtman ER. Protein oxidation in aging, disease, and oxidative stress. J Biol Chem 1997;272:20313–6.
  • Dalle-Donne I, Rossi R, Giustarini D, Milzani A, Colombo R. Protein carbonyl groups as biomarkers of oxidative stress. Clin Chim Acta 2003;329:23–38.
  • Himmelfarb J, McMonagle E, McMenamin E. Plasma protein thiol oxidation and carbonyl formation in chronic renal failure. Kidney Int 2000;58:2571–8.
  • Li H, Forstermann U. Nitric oxide in pathogenesis of vascular disease. J Pathol 2000;190:224–54.
  • Kalayci R, Kaya M, Elmas I, Arican N, Ahishali B, Uzun H, Bilgic B, Kucuk M, Kudat H. Effects of atorvastatin on blood-brain barrier permeability during l-NAME hypertension followed by angiotensin-II in rats. Brain Res 2005; 1042:184–93.
  • Kurowska EM. Nitric oxide therapies in vascular diseases. Curr Pharmacol Design 2002;8:155–66.
  • Cayatte AJ, Palacino JJ, Horten K, Cohen RA. Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. Arterioscler Thromb 1994;14:753–9.
  • Baylis C, Mitruka B, Deng A. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest 1992;90:278–81.
  • Peterson DA, Peterson DC, Archer S, Weir EK. The non specificity of specific nitric oxide synthase inhibitors. Biochem Biophys Res Commun 1992;187:797–801.
  • Balci H, Balci H, Genc H, Papila C, Can G, Papila B, Yanardag H, Uzun H. Serum lipid hydroperoxide levels and paraoxonase activity in patients with lung, breast, and colorectal cancer. J Clin Lab Anal 2012;26:155–60.
  • Reznick AZ, Packer L. Oxidative damage to proteins: spectrophotometric method for carbonyl assay. Methods Enzymol 1994;233:357–63.
  • Hu ML. Measurement of protein thiol groups and glutathione in plasma. Methods Enzymol 1994;233:381–5.
  • Nourooz Zadeh J. Ferrous ion oxidation in presence of xylenol orange for detection of lipid hydroperoxides in plasma. Methods Enzymol 1999;300:58–62.
  • Suda O, Tsutsui M, Morishita T, Tanimoto A, Horiuchi M, Tasaki H, Huang PL, Sasaguri Y, Yanagihara N, Nakashima Y. Long-term treatment with N(omega)-nitro-L-arginine methyl ester causes arteriosclerotic coronary lesions in endothelial nitric oxide synthase-deficient mice. Circulation 2002;106:1729–5.
  • Zhou MS, Schulman IH, Raij L. Nitric oxide, angiotensin II, and hypertension. Semin Nephrol 2004;24:366–8.
  • Konukoglu D, Serin O, Turhan MS. Plasma leptin and its relationship with lipid peroxidation and nitric oxide in obese female patients with or without hypertension. Arch Med Res 2006;37:602–6.
  • Redón J, Oliva MR, Tormos C, Giner V, Chaves J, Iradi A, Sáez GT. Antioxidant activities and oxidative stress byproducts in human hypertension. Hypertension 2003; 41:1096–101.
  • Cardoso AM, Martins CC, Fiorin FD, Schmatz R, Abdalla FH, Gutierres J, Zanini D, Fiorenza AM, Stefanello N, Serres JD, Carvalho F, Castro VP, Mazzanti CM, Royes LF, Belló Klein A, Goularte JF, Morsch VM, Bagatini MD, Schetinger MR. Physical training prevents oxidative stress in L-NAME-induced hypertension rats. Cell Biochem Funct 2013;31:136–51.
  • Yokoyama M. Oxidant stress and atherosclerosis. Curr Opin Pharmacol 2004;4:110–5.
  • Kelm M. Nitric oxide metabolism and breakdown. Biochim Biophys Acta 1999;1411:273–89.
  • Borgeraas H, Strand E, Ringdal Pedersen E, Dierkes J, Ueland PM, Seifert R, Wilberg ER, Bohov P, Berge RK, Nilsen DW, Nygård O. Omega-3 status and the relationship between plasma asymmetric dimethylarginine and risk of myocardial infarction in patients with suspected coronary artery disease. Cardiol Res Pract 2012;2012:201742.
  • Boger RH. Association of asymmetric dimethylarginine and endothelial dysfunction. Clin Chem Lab Med 2003; 41:1467–72.
  • Bode-Böger SM, Böger RH, Kienke S, Junker W, Frölich JC. Elevated l-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary l-arginine in hypercholesterolemic rabbits. Biochem Biophys Res Commun 1996;219:598–603.
  • Singh U, Devaraj S, Jialal I, Siegel D. Comparison effect of atorvastatin (10 versus 80 mg) on biomarkers of inflammation and oxidative stress in subjects with metabolic syndrome. Am J Cardiol 2008;102:321–5.
  • Harangi M, Seres I, Varga Z, Emri G, Szilvássy Z, Paragh G, Remenyik E. Atorvastatin effect on high-density lipoprotein-associated paraoxonase activity and oxidative damage. Eur J Clin Pharmacol 2004;60:685–91.
  • Franzoni F, Quinones-Galvan A, Regoli F, Ferrannini E, Galetta F. A comparative study of the in vitro antioxidant activity of statins. Int J Cardiol 2003;90:317–21.
  • Aydin S, Uzun H, Sozer V, Altug T. Effects of atorvastatin therapy on protein oxidation and oxidative DNA damage in hypercholesterolemic rabbits. Pharmacol Res 2009; 59:242–7.
  • Boger RH, Bode-Boger SM, Frolich JC. The arginine-nitric oxide pathway: role in atherosclerosis and therapeutic implications. Atherosclerosis 1996;127:1–11.
  • Wagner AH, Kohler T, Ruckschloss U, Just I, Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 2000;20:61–9.
  • Parihar A, Parihar MS, Zenebe WJ, Ghafourifar P. Statins lower calcium-induced oxidative stress in isolated mitochondria. Hum Exp Toxicol 2012;31:355–63.
  • Antoniades C, Bakogiannis C, Tousoulis D, Reilly S, Zhang MH, Paschalis A, Antonopoulos AS, Demosthenous M, Miliou A, Psarros C, Marinou K, Sfyras N, Economopoulos G, Casadei B, Channon KM, Stefanadis C. Preoperative atorvastatin treatment in CABG patients rapidly improves vein graft redox state by inhibition of Rac1 and NADPH-oxidase activity. Circulation 2010;122:S66–73.
  • Antoniades C, Bakogiannis C, Leeson P, Guzik TJ, Zhang MH, Tousoulis D, Antonopoulos AS, Demosthenous M, Marinou K, Hale A, Paschalis A, Psarros C, Triantafyllou C, Bendall J, Casadei B, Stefanadis C, Channon KM. Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling. Circulation 2011;124:335–45.
  • Sezer ED, Sozmen EY, Nart D, Onat T. Effect of atorvastatin therapy on oxidant-antioxidant status and atherosclerotic plaque formation. Vasc Health Risk Manag 2011;7: 333–43.
  • Elmadhun NY, Lassaletta AD, Chu LM, Liu Y, Feng J, Sellke FW. Atorvastatin increases oxidative stress and modulates angiogenesis in Ossabaw swine with the metabolic syndrome. J Thorac Cardiovasc Surg 2012;144:1486–93.
  • Juncos LI, Martín FL, Baigorria ST, Pasqualini ME, Fiore MC, Eynard AR, Juncos LA, García NH. Atorvastatin improves sodium handling and decreases blood pressure in salt-loaded rats with chronic renal insufficiency. Nutrition 2012;28:e23–8.
  • Pignatelli P, Carnevale R, Pastori D, Cangemi R, Napoleone L, Bartimoccia S, Nocella C, Basili S, Violi F. Immediate antioxidant and antiplatelet effect of atorvastatin via inhibition of Nox2. Circulation 2012;126:92–103.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.